摘要
目的检测CIP2AmRNA在肝细胞癌中的表达，探讨其与临床病理因素和预后的关系。方法用半定量RT-PCR检测4株人肝癌细胞系、1株永生化肝细胞系以及120例肝细胞癌组织、癌旁肝组织和20例正常无肝硬化肝组织中CIP2AmRNA的表达，并结合肝癌临床病理因素及预后进行分析。结果CIP2AmRNA在人肝癌细胞系Hep—G2、MHCC-97H、SMMC-7721、BEL-7402中均表达，而在永生化肝细胞系L-02中无表达。CIP2AmRNA在肝癌组织中的阳性率（78．3％）明显高于癌旁肝组织（28．3％）和正常无肝硬化肝组织（5．0％）（P〈0．01）。肝癌组织CIP2AmRNA的表达与肿瘤大小、病理分级和TNM分期相关（P〈0．05）。肝癌组织中CIP2AmRNA阳性组和阴性组5年总生存率分别为44．5％和65．1％，5年无瘤生存率分别为30．1％和53．7％，差异均有统计学意义（P〈0．05）。结论CIP2AmRNA在肝癌细胞系及肝癌组织中高表达，可能在肝癌发生发展中发挥重要作用，可以作为预后预测的一个重要参考指标。
Objective This study is to explore the expression of CIP2A mRNA in hepatocellular carcinoma （HCC）, and its correlations with clinicopathologic features and prognosis of HCC patients. Methods CIP2A mRNA expression was analyzed in four liver cancer cell lines （Hep-G2, MHCC97, SMMC-7721 and BEL-7402）, one immortalized liver cell line L-O2, neoplastic tissues and adjacent matched non-neoplastic liver tissues in 120 HCC patients and normal liver tissues of 20 cases using semi-quantitative reverse transcription-polymerase chain reaction （RT-PCR）. The correlations between CIP2A mRNA and clinicopathologic features and prognosis of HCC were analyzed. Results CIP2A mRNA was detected in Hep-G2, MHCC-97H, SMMC-7721 and BEL-7402, but not in L-O2. The positive rate of CIP2A mRNA expression was significantly increased in HCC tissues （78.3%） than in adjacent matched non-neoplastic liver tissues （28.3%） and normal liver tissues （5.0%, P〈0.01）. CIP2A mRNA expression was correlated with tumor size, differentiation and TNM stage （P〈0.05）. Patients with positive expression of CIP2A mRNA had lower overall survival and diseasefree survival rates. Conclusions CIP2A mRNA, which is highly expressed in liver cancer cell lines and HCC tissues, may be involved in hepatocarcinogenesis. CIP2A mRNA may be a valuable biomarker for assessing the prognosis of HCC.
出处
《中华肝胆外科杂志》
CAS
CSCD
北大核心
2011年第3期248-252,共5页
Chinese Journal of Hepatobiliary Surgery
基金
基金项目：国家自然科学基金（30872489和30972916）
